Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside [Yahoo! Finance]
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The analyst's bullish view is centered around optimism associated with attractive opportunities for Vaxart's ‘differentiated' oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine. Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside. “VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards,” the analyst writes. “We think oral vaccines hold unique properties that may complement intramuscular vaccines to fulfill global healthcare promise,” the analyst adds. Also Read: Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering Although norovirus poses significant global health and economic challenges, there is currently no approved vaccine. With an estimated market potential of $5 billion-10 billion due to the unmet need, a norovirus vaccine could
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical DysplasiaGlobeNewswire
- Oppenheimer starts Vaxart at outperform, cites oral vaccine focus [Seeking Alpha]Seeking Alpha
- Vaxart, Inc. (NASDAQ: VXRT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.MarketBeat
- Vaxart Second Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]Yahoo! Finance
VXRT
Earnings
- 8/8/24 - Miss
VXRT
Sec Filings
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- 7/5/24 - Form 8-K
- VXRT's page on the SEC website